2018.08.08

I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

Aug 8, 2018, I-Mab Biopharma (“I-Mab”), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune disease, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today that I-Mab has Submitted an investigational n...

2018.08.01

I-Mab Biopharma Announces New CFO

Jul 31, 2018, I-Mab Biopharma (“I-Mab”), a Shanghai-based biotech company focusing on innovative biologics in oncology and autoimmune disease, today announced the appointment of Jielun Zhu as Chief Financial Officer (CFO).

2018.06.29

I-Mab Successfully Raised US$220 Million in Series C Funding

I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for $220 million USD, representing one of the largest amounts ever raised in Series C by an innovative biotech company in China.

2018.06.07

I-Mab Biopharma Opens US Office in Rockville, Maryland

I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for $220 million USD, representing one of the largest amounts ever raised in Series C by an innovative biotech company in China.

2017.12.25

I-Mab Biopharma signs licensing agreement for HyLeukin with Genexine

I-Mab receives exclusive development and commercialization rights to HyLeukin in China, China Taiwan, Hong Kong and Macao Genexine, a clinical stage biotechnology company developing innovative biologics, today announced the signing of a licensing agreement with I-Mab to develop and commercialize a ...

2017.03.22

Official Website Online!

With all our efforts, Third Venture Biopharma's official website (in Chinese) was officially in public test phase on 21 March 2017. We hope that we can serve for our clients in a more prudent and professional manner. TVB will consistently move forward responsible for our staff and various clients.